Featured
-
Head of Nepalese HTC discusses WBDR in video
Bishesh Sharma Poudyal, MD, talks with Donna Coffin, WFH Director, Research & Public Policy about the impact the WFH World Bleeding Disorders Registry (WBDR) is having on the Civil Service...
-
World Hemophilia Day and “Reaching Out: The First Step to Care”
On April 17 of this year, our community will come together to celebrate World Hemophilia Day. The theme of this year’s big day is “The...
-
Warm welcome for Alain Baumann and the WFH in India
Alain Baumann, CEO of the World Federation of Hemophilia (WFH), visited the daycare centre of KEM Hospital, in Mumbai, India, on December 6, 2018—and was...
-
Medical Student, sister, carrier—one youth leader’s story
Jo Kroll, a native of Tartu, Estonia, barely remembers a time in her life when bleeding disorders were not part of her day-to-day life. At...
-
WFH publication explores challenges and opportunities of gene therapy
In the first of a series of round table meetings, the World Federation of Hemophilia (WFH) Gene Therapy Round Table was convened in April 2018...
-
The Government of Tunisia affirms support to patients with bleeding disorders
On November 15, 2018, the Ministry of Health of Tunisia signed a Memorandum of Understanding with the World Federation of Hemophilia (WFH) providing a framework...
-
Happy new year from the WFH
The World Federation of Hemophilia (WFH) wishes you, your friends, your family, and the whole global bleeding disorders community a wonderful new year. Happy 2019!
-
WFH supports MASAC’s recommendation on the risks of gene therapy trials for hemophilia
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #254, entitled, “MASAC Document Regarding Risks of Gene Therapy Trials for Hemophilia”. MASAC’s recommendation...
-
Sunny skies to wintry days: one youth leader’s journey
Chavez Edgecombe loves a challenge, including one most would think twice about accepting: moving from the warm climes of Nassau, Bahamas to pursue a degree...
-
WFH Medical Advisory Board (MAB) supports MASAC’s recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #255 entitled, “Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia...
